<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01337557</url>
  </required_header>
  <id_info>
    <org_study_id>MAC-03-11</org_study_id>
    <nct_id>NCT01337557</nct_id>
  </id_info>
  <brief_title>Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses</brief_title>
  <official_title>Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hom, Milton M., OD, FAAO</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hom, Milton M., OD, FAAO</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess if BEPREVE (bepotastine besilate ophthalmic solution)
      1.5% will have an effect on contact lens wear in patients with contact lens intolerance due
      to allergic conjunctivitis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">November 2011</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Questionnaire</measure>
    <time_frame>8 weeks</time_frame>
    <description>Contact lens comfort and wearing times (measured in hours)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Bepotastine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bepotastine</intervention_name>
    <description>1.5% bid</description>
    <arm_group_label>Bepotastine</arm_group_label>
    <other_name>Bepreve</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of allergic conjunctivitis

          -  History of contact lens intolerance

          -  Between the ages of 18 and over inclusive.

          -  Males or females

          -  Patient is in generally good &amp; stable overall health.

          -  Patient likely to comply with study guidelines &amp; study visits. Informed consent
             signed.

          -  Are willing/able to return for all required study visits.

          -  Are willing/able to follow instructions from the study investigator and his/her staff.

          -  If a woman capable of becoming pregnant, agree to have urine pregnancy testing
             performed at screening (must be negative) and agree to use a medically acceptable form
             of birth control throughout the study duration and for at least one week prior to and
             after completion of the study. Women considered capable of becoming pregnant include
             all females who have experienced menarche and who have not experienced menopause (as
             defined by amenorrhea for greater than 12 consecutive months) or have not undergone
             successful surgical sterilization (hysterectomy, bilateral tubal ligation, or
             bilateral oophorectomy).

          -  Have signed informed consent approved by Institutional Review Board or Independent
             Ethics Committee.

        Exclusion Criteria:

          -  Corneal refractive surgery within 6 months of this study.

          -  Current use of Restasis

          -  Intra-ocular surgery within 6 months or ocular laser surgery within 6 months.

          -  Pregnant or lactating women.

          -  Ocular pathology (includes glaucoma and cataract), which could impact results and/or
             place patient at risk.

          -  Systemic or injected corticosteroids (including oral, parenteral, intravenous, rectal)
             30 days;

          -  Nasal or inhaled or ocular corticosteroids 14 days;

          -  Nasal or inhaled ipratropium bromide (or atropine), inhaled nedocromil, or nasal,
             inhaled, or ophthalmic sodium cromolyn 14 days;

          -  Agents with antihistaminic/anticholinergic activity (e.g. antidepressants,
             antipsychotics) 14 days;

          -  Leukotriene pathway modifiers (Accolate, Singulair, Zyflo) 10 days;

          -  Ocular anti-allergy medications including lodoxamide (Alomide), olopatadine
             (Patanol/Pataday), emedastine difumarate (Emadine), epinastine (Elestat),
             levocabastine (Livostin) 7 days;

          -  Non-steroidal anti-inflammatory ophthalmics including bromfenac (Xibrom), ketorolac
             (Acular/Acuvail), nepafenac (Nevanac), flurbiprofen (Ocufen), suprofen (Profenal),
             diclofenac (Voltaren) 7 days;

          -  OTC ophthalmic decongestant, antihistamine, or decongestant/antihistamine combinations
             3 days;

          -  Other anticholinergic agents 3 days

          -  Immunotherapy injection 1 day.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milton M Hom, OD FAAO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private Practice</affiliation>
  </overall_official>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2011</study_first_submitted>
  <study_first_submitted_qc>April 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2011</study_first_posted>
  <last_update_submitted>April 18, 2011</last_update_submitted>
  <last_update_submitted_qc>April 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Milton M. Hom, OD, FAAO.</name_title>
    <organization>Private Practice</organization>
  </responsible_party>
  <keyword>Allergic conjunctivitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

